Lamassu Biotech

Lamassu Biotech is a private, clinical-stage biotech advancing a pipeline of novel small molecule therapeutics with an emphasis on accelerated development timelines. Its lead programs include SA53, a first-in-class oncology candidate targeting p53 wild-type tumors in Phase I/II, and RABI-767 for acute pancreatitis, which has progressed to Phase II. The company's strategy centers on a collaborative, translational research model that bridges academia and industry to de-risk and expedite the path from discovery to definitive clinical testing.

Collaborative translational science model focused on accelerating early-stage assets with strong preclinical data into clinical proof-of-concept through strategic development planning and partnership.

The oncology space targeting p53 is intensely competitive, with numerous large pharma and biotech firms pursuing complementary strategies. The acute pancreatitis therapeutic landscape is less crowded but still features established players and other investigational agents. Lamassu's differentiation lies in its accelerated translational model and novel compound mechanisms.